The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health ... inflated insulin list prices, ...

An FTC official said the case argues that PBMs ... a report refuting arguments that the industry raises costs. The drug middlemen say they’re a necessary counterweight to the unchecked ...

endangering patients,” said the FTC's Chair, Lina Khan. “Our inquiry requests information on the factors driving these shortages and scrutinises the practices of opaque drug middlemen.” ...

CVS Health, Cigna and UnitedHealth Group are demanding that FTC Chairwoman Lina Khan and two other commissioners recuse themselves from a lawsuit accusing the company and other drug middlemen of ...

Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

PBMs serve as middlemen, negotiating the ... The FTC’s Changing Views on PBMs A 2005 FTC report found that PBM negotiations lower average drug prices and insurance premiums.

NEW YORK, July 10 (Bernama-Xinhua) -- The US Federal Trade Commission (FTC) criticised pharmacy benefit managers in a 71-page report on Tuesday, stating that "these powerful middlemen may be profiting ...

In its complaint, the FTC alleges that PBMs followed a “chase-the-rebate strategy,” which led to soaring insulin list prices and made it harder for Americans to get the crucial medication ...

The drug middlemen say they’re a necessary counterweight to the unchecked power of pharmaceutical companies to set prices. The insulin market is dominated by three manufacturers: Eli Lilly & Co., ...